Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.

Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM.

J Thorac Oncol. 2007 Jul;2(7):638-44.

2.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):309-12. Chinese.

PMID:
16875636
3.

A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.

Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J.

Lung Cancer. 2007 Jun;56(3):363-9. Epub 2007 Feb 15.

PMID:
17306906
4.

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group..

Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.

PMID:
26522337
5.

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.

Lara PN Jr, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR.

J Thorac Oncol. 2006 Feb;1(2):126-34.

6.

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

Pérol M, Léna H, Thomas P, Robinet G, Fournel P, Coste E, Belleguic C, Le Caer H, Blanchon F, Vergnenègre A, Vernejoux JM, Schuller-Lebeau MP, Pham E.

Ann Oncol. 2002 May;13(5):742-7.

PMID:
12075743
7.

A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.

Binder D, Hackenthal M, Graseck L, Schweisfurth H, Schäper C, Krüll M, Temmesfeld-Wollbrück B, Suttorp N, Beinert T, Hellriegel KP.

J Thorac Oncol. 2009 Sep;4(9):1144-7. doi: 10.1097/JTO.0b013e3181b0f0de.

8.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP.

J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1.

PMID:
12837811
9.

Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.

Mok TS, Ho S, Chan G, Ho WM, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Lee Y, Lam KC.

J Thorac Oncol. 2007 Sep;2(9):838-44.

10.

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.

Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS.

Lung Cancer. 2001 Nov;34(2):271-7.

PMID:
11679186
11.

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C.

J Clin Oncol. 1997 Feb;15(2):750-8.

PMID:
9053501
12.

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.

Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP.

Int J Cancer. 2002 Mar 1;98(1):141-7.

13.

Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.

Ohe Y, Niho S, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Kunitoh H, Saijo N, Nishiwaki Y.

Jpn J Clin Oncol. 2001 Mar;31(3):100-6.

PMID:
11336320
14.

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL.

Lung Cancer. 2001 Aug-Sep;33(2-3):277-87.

PMID:
11551423
15.

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.

Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, Sakamaki K, Shibuya M, Watanabe K.

BMC Cancer. 2015 Oct 19;15:740. doi: 10.1186/s12885-015-1756-1.

16.

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.

Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.

Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. doi: 10.1007/s00280-009-1235-y. Epub 2010 Jan 21.

PMID:
20091311
17.

Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.

Hosomi Y, Ohe Y, Mito K, Uramoto H, Moriyama E, Tanaka K, Kodama K, Niho S, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Kakinuma R, Nishiwaki Y.

Jpn J Clin Oncol. 1999 Nov;29(11):546-9.

PMID:
10678557
18.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group..

Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190. Epub 2015 Apr 23.

19.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

PMID:
25662596
20.

Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.

Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S, Mori K, Tsukiyama I, Tamura T.

J Thorac Oncol. 2006 Oct;1(8):810-5.

Supplemental Content

Support Center